Oral anticoagulation in nonvalvular atrial fibrillation in clinical practice: Impact of CHADS2 score on outcome

Cardiology

Volumn 115, Issue 3, 2010, Pages 200-204

  Ortiz, Martín Ruiz ^a   Romo, Elías ^a   Mesa, Dolores ^a   Delgado, Mónica ^a   Anguita, Manuel ^a   Castillo, Juan C ^a   Arizón, José M ^a   De Lezo, José Suárez ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Atrial fibrillation; Prevention; Stroke

Indexed keywords

ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CHADS2 SCORE; CLINICAL PRACTICE; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; OUTPATIENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCORING SYSTEM; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; EMBOLISM; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HEALTH STATUS INDICATORS; HEMORRHAGE; HUMANS; MALE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPAIN; SURVIVAL RATE;

EID: 76549135620     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000284450     Document Type: Article

References (15)

1. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870. (Pubitemid 32537350)
2. Aihara M, Guyatt G: The risk factors for thromboembolism in nonvalvular atrial fibrillation and CHADS 2 scoring in Japan. Circ J 2007; 71: 1999. (Pubitemid 350261432)
3. Ruiz Ortiz M, Romo E, Mesa D, Delgado M, Anguita M, Lopez Granados A, Castillo JC, Arizon JM, Suarez de Lezo J: Predicting embolic events in patients with nonvalvular atrial fibrillation: evaluation of the CHADS 2 score in a Mediterranean population. Rev Esp Cardiol 2008; 61: 29-35. (Pubitemid 351573755)
4. Rietbrock S, Heeley E, Plumb J, van Staa T: Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age 75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS 2 ) risk stratification scheme. Am Heart J 2008; 156: 57-64. (Pubitemid 351877101)
5. Lip G, Nieuwlaat R, Pisters R, Lane D, Crijns H: Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2009, E-pub ahead of print. DOI 10.1378/chest.09-1584.
6. Poli D: Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS 2 score. Thromb Res 2007; 121: 347-352.
7. Hylek EM: Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696. (Pubitemid 46842784)
8. Ruiz Ortiz M, Romo Penas E, Franco Zapata M, Mesa Rubio D, Anguita Sanchez M, Lopez Granados A, Arizon del Prado JM, Valles Belsue F: A prospective protocol increases oral anticoagulant prescription in patients with chronic, nonvalvular atrial fibrillation. Rev Esp Cardiol 2003; 56: 971-977. (Pubitemid 37407558)
9. Heras M, Fernandez Ortiz A, Gomez Guindal JA, Iriarte JA, Lidon RM, Perez Gomez F, Roldan I: Practice guidelines of the Spanish Society of Cardiology: recommendations for the use of antithrombotic treatment in cardiology. Rev Esp Cardiol 1999; 52: 801-820. (Pubitemid 29513090)
10. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J 2001; 22: 1852-l923.
11. Almendral Garrote J, Marin Huerta E, Medina Moreno O, Peinado Peinado R, Perez Alvarez L, Ruiz Granell R, Vinolas Prat X: Practice guidelines of the Spanish Society of Cardiology on cardiac arrhythmias. Rev Esp Cardiol 2001; 54: 307-367. (Pubitemid 32303156)
12. Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-691. (Pubitemid 24087846)
13. Healey JS, Hart RG, Pogue J, Pfeffer MA, Hohnloser SH, De Caterina R, Flaker G, Yusuf S, Connolly SJ: Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk. The Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVEW). Stroke 2008; 39: 1482-1486.
14. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al: ACC/AHA/ ESC 2006 guidelines for the management of patients with atrial fibrillation. Europace 2006; 8: 651-745.
15. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.